ArticleInfection2026
Multidrug-resistant Klebsiella pneumoniae in oncology intensive care units: selected genetic markers and clinical predictors.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant (MDR) Klebsiella pneumoniae poses a critical threat in oncology intensive care units (ICUs), particularly in low- and middle-income countries like Egypt, where immunocompromised patients are at high risk from invasive procedures. This study aimed to characterize antimicrobial resistance patterns and molecular features of MDR K. pneumoniae isolates and to explore clinical and genetic markers associated with resistance burden.
methodsFifty K. pneumoniae isolates were recovered from cancer patients at Shefa Al Orman Oncology Hospital (Luxor, Egypt). Susceptibility testing was performed using VITEK® 2. Resistance genes (OmpK35, QnrB, AcrAB, OqxA, and Sul2) were detected via PCR. Resistance burden was quantified as a resistance score (R-score) and analyzed against clinical and genetic variables using non-parametric tests and regression models.
resultsAll isolates (100%) were resistant to β-lactams. High resistance rates were observed for carbapenems (78-84%), fluoroquinolones (84%), aminoglycosides (76-80%), and trimethoprim-sulfamethoxazole (86%), while tetracycline (40%) and tigecycline (10%) showed lower resistance. Genetic analysis revealed Sul2 (100%), OmpK35 (94%), OqxA (92%), QnrB (90%), and AcrAB (68%). Prior hospitalization and antibiotic use within three months were the only independent risk factors for higher R-scores (p = 0.041). Patient mortality reached 46%.
conclusionMDR K. pneumoniae in oncology ICUs shows extensive resistance and multiple genetic associations. Prior healthcare exposure significantly increases resistance burden, emphasizing the urgent need for stringent antimicrobial stewardship and targeted infection control measures.
Indexed as
Identifiers
42010196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.